2I9.F KAROLINSKA DEVELOP.AB
- Market cap
- EUR 75.9K
- P/E
- -
- P/B
- 0.00x
- ROE
- -143.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 2I9.F undervalued?
Graham numberThe Graham number of KAROLINSKA DEVELOP.AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
KAROLINSKA DEVELOP.AB fundamental analysis
No fundamental analysis for KAROLINSKA DEVELOP.AB yet.
KAROLINSKA DEVELOP.AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About KAROLINSKA DEVELOP.AB
KDventures AB, formerly known as Karolinska Development AB (publ), is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, innovative drug development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in …
Full company profileKAROLINSKA DEVELOP.AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
KAROLINSKA DEVELOP.AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 2.30M | 2.01M | 1.84M | 1.67M | 1.48M |
| Operating Income | -31.8M | -27.6M | -31.4M | -20.9M | -22.0M |
| EBITDA | -86.6M | 6.18M | -7.00M | -193M | -21.0M |
| Net Income | -88.1M | 5.39M | -8.10M | -194M | -970M |
| EPS | -0.27 | 0.02 | -0.02 | -0.59 | -1.28 |
| Balance Sheet | |||||
| Total Assets | 1.25B | 1.26B | 1.25B | 1.05B | 687M |
| Total Liabilities | 10.2M | 11.6M | 13.3M | 8.34M | 10.8M |
| Shareholders' Equity | 1.24B | 1.25B | 1.24B | 1.04B | 676M |
| Cash & Short-term Investments | 131M | 85.3M | 42.0M | 23.9M | 51.4M |
| Cash Flow | |||||
| Operating Cash Flow | -32.5M | -25.0M | -27.8M | -26.1M | -18.3M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -32.5M | -25.0M | -27.8M | -26.1M | -18.3M |
| Ratios | |||||
| ROE | -7.1% | 0.4% | -0.7% | -18.6% | -143.5% |
| ROA | -7.0% | 0.4% | -0.6% | -18.4% | -141.2% |
| Net Profit Margin | -3,831.4% | 267.4% | -440.8% | -11,601.1% | -65,739.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
KAROLINSKA DEVELOP.AB dividends
KAROLINSKA DEVELOP.AB has not paid dividends in the last 5 fiscal years.
Who owns KAROLINSKA DEVELOP.AB
- Insiders 47.22%
- Institutions 16.49%
- Public & others 36.29%
- Shares outstanding 756M
- Free float 451M
KAROLINSKA DEVELOP.AB company profile
- Company name
- KAROLINSKA DEVELOP.AB
- Ticker
- 2I9.F
- ISIN
- SE0002190926
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- Nanna Svartz väg 6A, Solna, Sweden, 17165
- Phone
- 46 8 52 48 60 70
- Website
- karolinskadevelopment.com
About KAROLINSKA DEVELOP.AB
KDventures AB, formerly known as Karolinska Development AB (publ), is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, innovative drug development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. KDventures AB was founded in 2003 and is based in Solna, Sweden with an additional office in Solna Sweden.
KAROLINSKA DEVELOP.AB management
7- Dr. Viktor Drvota M.D., Ph.D.Chief Executive Officer · born 1965
- Mr. Hans Christopher TollChief Financial Officer · born 1968
- Ms. Eva MontgomerieHead of Accounting · born 1958
- Mr. Johan DighedGeneral Counsel & Deputy CEO · born 1973
- Mr. Tse PingSenior Strategic Advisor · born 1952
- Dr. John Öhd M.D., Ph.D.Senior Advisor & Venture Partner · born 1971
- Mr. Mathias FrenzelInvestment Analyst · born 1998